Secondary pulmonary hypertension: haemodynamic effects of torasemide versus furosemide.
OBJECTIVE
Experimental data have demonstrated controversial results regarding loop diuretics and their influence on the pulmonary vasculature. The aim of this pilot study was to compare the effect of torasemide versus furosemide on systemic and pulmonary haemodynamics in patients with secondary pulmonary hypertension.


METHODS
Twenty-one patients were enrolled in this double-blind, randomized trial: the furosemide group (n = 11) received 40 mg intravenously (IV) and 80 mg orally whereas the torasemide group (n = 10) received 20 mg IV and 20 mg orally. Haemodynamic variables were documented and endothelin-1 and arterial angiotensin-II plasma levels were simultaneously analysed at baseline (T0), 5 minutes after IV administration (T1), at baseline prior to oral administration (T2), and 60 minutes after oral administration (T3).


RESULTS
Cardiac output (relative treatment effect over time between groups; p = 0.03) increased significantly in the torasemide group compared with the furosemide group. In the furosemide group, a significant increase in arterial angiotensin-II (AT-II) plasma levels was observed compared with the torasemide group (relative treatment effect over time between groups; p = 0.031).


CONCLUSIONS
Torasemide increased cardiac output (relative treatment effect over the time), whereas treatment with furosemide significantly increased arterial AT-II plasma levels. A possible explanation for these findings might be activation of the renin-angiotensin system by furosemide. However, the underlying pathomechanism remains to be established and evidence from an adequately powered trial is needed to determine if furosemide aggravates cardiac function by increasing AT-II plasma levels.
von Dossow
Vera
V
Department of Anaesthesiology and Intensive Care Medicine, Charité University Medicine Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany. vera.vdossow@charite.de
Spies
Claudia
C
Schenk
Hannes
H
Schlesinger
Sabine
S
von Heymann
Christian
C
D000284:Administration, Oral; D000368:Aged; D000804:Angiotensin II / Q000097:blood; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002302:Cardiac Output / Q000187:drug effects; D004232:Diuretics / Q000008:administration & dosage / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D019332:Endothelin-1 / Q000097:blood; D005260:Female; D005665:Furosemide / Q000008:administration & dosage / Q000627:therapeutic use*; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000097:blood / Q000209:etiology / Q000503:physiopathology*; D007275:Injections, Intravenous; D008168:Lung / Q000098:blood supply / Q000187:drug effects / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011446:Prospective Studies; D013318:Stroke Volume / Q000187:drug effects; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use*; D000077786:Torsemide; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D004232:Diuretics; D019332:Endothelin-1; D013449:Sulfonamides; D000804:Angiotensin II; D005665:Furosemide; D000077786:Torsemide